Southwest Oncology Group 0408: Phase II trial of neoadjuvant capecitabine/oxaliplatin/bevacizumab for resectable colorectal metastases in the liver

被引：9

作者：

Abdalla, Eddie K. ^{[1
]}

Eng, Cathy ^{[1
]}

Madary, Alice ^{[1
]}

Vauthey, Jean-Nicolas ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Surg, Houston, TX 77030 USA

来源：

CLINICAL COLORECTAL CANCER | 2006年 / 5卷 / 06期

关键词：

5-fluorouracil; leucovorin; R0; resection;

D O I：

10.3816/CCC.2006.n.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：436 / 439

页数：4

共 16 条

[1]

Abdalla EK, 2004, ANN SURG, V239, P818, DOI 10.1097/01.sla.0000128305.90650.71

[2] Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer [J].

Borner, MM ;

Dietrich, D ;

Stupp, R ;

Moran, R ;

Honegger, H ;

Wernli, M ;

Herrmann, R ;

Pestalozzi, BC ;

Saletti, P ;

Hanselmann, S ;

Müller, S ;

Brauchli, P ;

Castiglione-Gertsch, M ;

Goldhirsch, A ;

Roth, AD .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) :1759-1766

[3] XELOX (capecitabine plus oxaliplatin):: Active first-line therapy for patients with metastatic colorectal cancer [J].

Cassidy, J ;

Tabernero, J ;

Twelves, C ;

Brunet, R ;

Butts, C ;

Conroy, T ;

Debraud, F ;

Figer, A ;

Grossmann, J ;

Sawada, N ;

Schöffski, P ;

Sobrero, A ;

Van Cutsem, E ;

Diaz-Rubio, E .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2084-2091

[4] Trends in long-term survival following liver resection for hepatic colorectal metastases [J].

Choti, MA ;

Sitzmann, JV ;

Tiburi, MF ;

Sumetchotimetha, W ;

Rangsin, R ;

Schulick, RD ;

Lillemoe, KD ;

Yeo, CJ ;

Cameron, JL .

ANNALS OF SURGERY, 2002, 235 (06) :759-765

[5] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].

de Gramont, A ;

Figer, A ;

Seymour, M ;

Homerin, M ;

Hmissi, A ;

Cassidy, J ;

Boni, C ;

Cortes-Funes, H ;

Cervantes, A ;

Freyer, G ;

Papamichael, D ;

Le Bail, N ;

Louvet, C ;

Hendler, D ;

de Braud, F ;

Wilson, C ;

Morvan, F ;

Bonetti, A .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947

[6] Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer - Analysis of 1001 consecutive cases [J].

Fong, Y ;

Fortner, J ;

Sun, RL ;

Brennan, MF ;

Blumgart, LH .

ANNALS OF SURGERY, 1999, 230 (03) :309-318

[7] Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer [J].

Giacchetti, S ;

Perpoint, B ;

Zidani, R ;

Le Bail, N ;

Faggiuolo, R ;

Focan, C ;

Chollet, P ;

Llory, JF ;

Letourneau, Y ;

Coudert, B ;

Bertheaut-Cvitkovic, F ;

Larregain-Fournier, D ;

Le Rol, A ;

Walter, S ;

Adam, R ;

Misset, JL ;

Lévi, F .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :136-147

[8]

Giantonio BJ, 2005, AM SOC CLIN ONC 2005

[9] A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer [J].

Goldberg, RM ;

Sargent, DJ ;

Morton, RF ;

Fuchs, CS ;

Ramanathan, RK ;

Williamson, SK ;

Findlay, BP ;

Pitot, HC ;

Alberts, SR .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :23-30

[10] Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study [J].

Hoff, PM ;

Ansari, R ;

Batist, G ;

Cox, J ;

Kocha, W ;

Kuperminc, M ;

Maroun, J ;

Walde, D ;

Weaver, C ;

Harrison, E ;

Burger, HU ;

Osterwalder, B ;

Wang, AO ;

Wong, R .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2282-2292

← 1 2 →